Brain histamine H1 receptor occupancy of orally administered antihistamines, bepotastine and diphenhydramine, measured by PET with 11C-doxepin

British Journal of Clinical Pharmacology

Volumn 65, Issue 6, 2008, Pages 811-821

  Tashiro, Manabu ^a   Duan, Xudong ^a   Kato, Motohisa ^b   Miyake, Masayasu ^a   Watanuki, Shoichi ^a   Ishikawa, Yoichi ^a   Funaki, Yoshihito ^a   Iwata, Ren ^a   Itoh, Masatoshi ^a   Yanai, Kazuhiko ^a,b  

^a TOHOKU UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

First generation antihistamine; Histamine H1 receptor occupancy; Placebo controlled crossover study design; Positron emission tomography; Second generation antihistamine

Indexed keywords

ANTIHISTAMINIC AGENT; BETOTASTINE; CARBON 11; CETIRIZINE; DIPHENHYDRAMINE; DOXEPIN; EPINASTINE; HISTAMINE H1 RECEPTOR; KETOTIFEN; TERFENADINE; CARBON; DIAGNOSTIC AGENT; HISTAMINE H1 RECEPTOR ANTAGONIST; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE;

ADULT; ALLERGIC DISEASE; AREA UNDER THE CURVE; ARTICLE; CINGULATE GYRUS; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FRONTAL CORTEX; HUMAN; HUMAN EXPERIMENT; INSULA; MALE; NORMAL HUMAN; OCCIPITAL CORTEX; ORBITAL CORTEX; PARIETAL LOBE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEDATION; SENSORIMOTOR CORTEX; SIDE EFFECT; SINGLE DRUG DOSE; TEMPORAL CORTEX; BRAIN; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; METABOLISM; METHODOLOGY; ORAL DRUG ADMINISTRATION; SCINTISCANNING; SLEEP STAGE;

ADMINISTRATION, ORAL; ADULT; BRAIN; CARBON RADIOISOTOPES; DIPHENHYDRAMINE; DOXEPIN; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; PIPERIDINES; POSITRON-EMISSION TOMOGRAPHY; PYRIDINES; RECEPTORS, HISTAMINE H1; SLEEP STAGES;

EID: 43549100586     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03143.x     Document Type: Article

References (45)

1. Yanai K, Tashiro M. The physiological and pathophysiological roles of neuronal histamine: an insight from human positron emission tomography studies. Pharmacol Ther 2007 113: 1 15.
2. Haas H, Panula P. The role of histamine and the tuberomamillary nucleus in the nervous system. Nat Rev Neurosci 2003 4: 121 30.
3. Holgate ST, Canonica GW, Simons FE, Taglialatela M, Tharp M, Timmerman H, Yanai K. Consensus Group on New-Generation Antihistamines (CONGA): present status and recommendations. Clin Exp Allergy 2003 33: 1305 24.
4. Casale TB, Blaiss MS, Gelfand E, Gilmore T, Harvey PD, Hindmarch I, Simons FE, Spangler DL, Szefler SJ, Terndrup TE, Waldman SA, Weiler J, Wong DF. First do no harm: managing antihistamine impairment in patients with allergic rhinitis. J Allergy Clin Immunol 2003 111: S835 42.
5. Brown RE, Stevens DR, Haas HL. The physiology of brain histamine. Prog Neurobiol 2001 63: 637 72.
6. Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, Ito K, Itoh M. Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995 116: 1649 55.
7. Okamura N, Yanai K, Higuchi M, Sakai J, Iwata R, Ido T, Sasaki H, Watanabe T, Itoh M. Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000 129: 115 23.
8. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Iwata R, Fujii T, Komemushi S, Ido T, Itoh M, Sasaki H, Watanabe T, Yanai K. Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol 2001 52: 501 9.
9. Tashiro M, Sakurada Y, Iwabuchi K, Mochizuki H, Kato M, Aoki M, Funaki Y, Itoh M, Iwata R, Wong DF, Yanai K. Central effects of fexofenadine and cetirizine: measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol 2004 44: 890 900.
10. Tashiro M, Mochizuki H, Sakurada Y, Ishii K, Oda K, Kimura Y, Sasaki T, Ishiwata K, Yanai K. Brain histamine H receptor occupancy of orally administered antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: a comparison of olopatadine and ketotifen. Br J Clin Pharmacol 2006 61: 16 26.
11. Ishibashi Y, Kawashima M, Harada S, Suzuki Y. [Phase I study of antiallergic agent, TAU-284 (betotastine besilate): study of inhibitory effect on intradermal reaction of histamine]. J Clin Therap Med 1997 13: 53 63.
12. Yokota H, Mizuuchi H, Maki T, Banno K, Sato T. [Phase I study of TAU-284: single oral administration in healthy male volunteers]. J Clin Therap Med 1997 13: 3 19.
13. Kawashima M, Harada S, Nakajima M. [Phase III study of TAU-284 (betotastine besilate) on chronic urticaria: a multicenter double blind comparative study with placebo]. J Clin Therap Med 2002 18: 13 31.
14. Murata T, Matsumoto Y, Suzuki T, Naito K, Takata I, Tsuzurahara K. [Effect of betotastine besilate (TAU-284), a novel anti-allergic agent, on experimental allergic rhinitis]. Arerugi 1997 46: 576 84.
15. Yato N, Murata T, Saito N, Sakai A, Kikuchi M, Tsuzurahara K, Narita H. [Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug]. Nippon Yakurigaku Zasshi 1997 110: 19 29.
16. Ueno M, Inagaki N, Nagai H, Koda A. Antiallergic action of betotastine besilate (TAU-284) in animal models: a comparison with ketotifen. Pharmacology 1998 57: 206 14.
17. Nakahara T, Urabe K, Moroi Y, Morita K, Furue M. Bepotastine besilate rapidly inhibits mite-antigen induced immediate reactions in atopic dermatitis. J Dermatol Sci 2003 32: 237 8.
18. Takahashi H, Ishida-Yamamoto A, Iizuka H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin Exp Dermatol 2004 29: 526 32.
19. Kato M, Nishida A, Aga Y, Kita J, Kudo Y, Narita H, Endo T. Pharmacokinetic and pharmacodynamic evaluation of central effect of the novel antiallergic agent betotastine besilate. Arzneimittelforschung 1997 47: 1116 24.
20. Kay GG, Harris AG. Loratadine: a non-sedating antihistamine. Review of its effects on cognition, psychomotor performance, mood and sedation. Clin Exp Allergy 1999 29 (Suppl. 3 147 50.
21. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, Arai H, Fujii T, Komemushi S, Itoh M, Sasaki H, Watanabe T, Yanai K. Differential cognitive effects of ebastine and (+)-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. Br J Clin Pharmacol 2002 53: 296 304.
22. Hindmarch I, Shamsi Z, Kimber S. An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002 32: 133 9.
23. Tashiro M, Horikawa E, Mochizuki H, Sakurada Y, Kato M, Inokuchi T, Ridout F, Hindmarch I, Yanai K. Effects of fexofenadine and hydroxyzine on brake reaction time during car-driving with cellular phone use. Hum Psychopharmacol 2005 20: 501 9.
24. Kumar S, Rurak DW, Riggs KW. Simultaneous determination of diphenhydramine, its N-oxide metabolite and their deuterium-labeled analogues in ovine plasma and urine using liquid chromatography/electrospray tandem mass spectrometry. J Mass Spectrom 1998 33: 1171 81.
25. Kanba S, Richelson E. Histamine H1 receptors in human brain labelled with [3H]doxepin. Brain Res 1984 304: 1 7.
26. Inoue I, Yanai K, Kitamura D, Taniuchi I, Kobayashi T, Niimura K, Watanabe T, Watanabe T. Impaired locomotor activity and exploratory behavior in mice lacking histamine H1 receptors. Proc Natl Acad Sci USA 1996 93: 13316 20.
27. Iwata R, Pascali C, Bogni A, Miyake Y, Yanai K, Ido T. A simple loop method for the automated preparation of (11C) raclopride from (11C) methyl triflate. Appl Radiat Isot 2001 55: 17 22.
28. Nakamura T, Hayashi Y, Watabe H, Matsumoto M, Horikawa T, Fujiwara T, Ito M, Yanai K. Estimation of organ cumulated activities and absorbed doses on intakes of several 11C labelled radiopharmaceuticals from external measurement with thermoluminescent dosimeters. Phys Med Biol 1998 43: 389 405.
29. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, Ishii K, Orihara H, Fukuda H, Satoh T, Kitamura K, Tanaka K, Takahashi S. Performance evaluation of a large axial field-of-view PET scanner SET-2400w. Ann Nucl Med 1997 11: 307 13.
30. Bergstrom M, Eriksson L, Bohm C, Blomqvist G, Litton J. Correction for scattered radiation in a ring detector positron camera by integral transformation of the projections. J Comput Assist Tomogr 1983 7: 42 50.
31. Inoue T, Oriuchi N, Kunio M, Tomiyoshi K, Tomaru Y, Aoyagi K, Amano S, Suzuki H, Aoki J, Sato T, Endo K. Accuracy of standardized uptake value measured by simultaneous emission and transmission scanning in PET oncology. Nucl Med Commun 1999 20: 849 57.
32. Mochizuki H, Kimura Y, Ishii K, Oda K, Sasaki T, Tashiro M, Yanai K, Ishiwata K. Simplified PET measurement for evaluating histamine H1 receptors in human brains using [11C]doxepin. Nucl Med Biol 2004 31: 1005 11.
33. Friston KJ, Holmes AP, Worsley KJ, Poline JP, Frith CD, Frackowiak RSJ. Statistical parametric maps in functional imaging: a general linear approach. Hum Brain Mapp 1995 2: 189 210.
34. Martinez D, Hwang D, Mawlawi O, Slifstein M, Kent J, Simpson N, Parsey RV, Hashimoto T, Huang Y, Shinn A, Van Heertum R, Abi-Dargham A, Caltabiano S, Malizia A, Cowley H, Mann JJ, Laruelle M. Differential occupancy of somatodendritic and postsynaptic 5HT (1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 2001 24: 209 29.
35. Rabiner EA, Wilkins MR, Turkheimer F, Gunn RN, de Haes JU, de Vries M, Grasby PM. 5-Hydroxytryptamine1A receptor occupancy by novel full antagonist 2-[4-[4-(7-chloro-2,3-dihydro-1,4-benzdioxyn-5-yl)-1-piperazinyl]butyl]-1, 2-benzisothiazol-3-(2H)-one-1,1-dioxide: a[11C][O-methyl-3H]-N-(2-(4-(2- methoxyphenyl)-1-piperazinyl) ethyl) -N-(2-py ridinyl) cyclohexanecarboxamide trihydrochloride (WAY-100635) positron emission tomography study in humans. J Pharmacol Exp Ther 2002 301: 1144 50.
36. Talairach J, Tournoux P. Co-planar Stereotaxic Atlas of the Human Brain. Stuttgart: Georg Thieme Verlag, 1988.
37. van Rij CM, Huitema AD, Swart EL, Greuter HN, Lammertsma AA, van Loenen AC, Franssen EJ. Population plasma pharmacokinetics of 11C-flumazenil at tracer concentrations. Br J Clin Pharmacol 2005 60: 477 85.
38. Martinez D, Broft A, Laruelle M. Imaging neurochemical endophenotypes: promises and pitfalls. Pharmacogenomics 2001 2: 223 37.
39. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T. New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999 29 (Suppl. 3 29 36 discussion 37 8.
40. Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Asakura M, Matsumura R, Itoh M. Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods Find Exp Clin Pharmacol 1995 17 (Suppl. C 64 9.
41. Hindmarch I, Shamsi Z, Stanley N, Fairweather DB. A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999 48: 200 6.
42. Dogan AS, Catafau AM, Zhou Y, Yanai K, Ravert H, Brasic J, Hilton J, Dannals B, Offord S, Wong DF. In vivo cerebral histamine receptor occupancy of three antihistamine drugs: an 11C-doxepin PET study. J Nucl Med 2001 42: 143P 144P.
43. Ohashi R, Kamikozawa Y, Sugiura M, Fukuda H, Yabuuchi H, Tamai I. Effect of P-glycoprotein on intestinal absorption and brain penetration of antiallergic agent bepotastine besilate. Drug Metab Dispos 2006 34: 793 9.
44. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999 27: 866 71.
45. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther 2004 308: 438 45.